Bz Pro Insights: Analyst Ratings for Avidity Biosciences (NASDAQ:RNA)

Monday, 16 September 2024, 12:00

Bz insights reveal 7 key analyst ratings on Avidity Biosciences (NASDAQ:RNA) that shape market perspectives. Avidity Biosciences shows an average price target of $68.86 with estimates reaching as high as $96.00 and as low as $53.00. This analysis reflects a positive sentiment, driven by a 4.33% increase in current performance metrics.
Benzinga
Bz Pro Insights: Analyst Ratings for Avidity Biosciences (NASDAQ:RNA)

Bz Pro Analysis of Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences has garnered attention from analysts who have forecasted significant price targets for the stock. Analysts suggest a 12-month average price target of $68.86, which can potentially reach a high estimate of $96.00 and a low estimate of $53.00. This variability reflects diverse perspectives among analysts regarding the company’s future performance.

Current Performance Metrics

  • Current Price Increase: 4.33%
  • Analyst Sentiment: Positive outlook
  • Market Movements: Influential factors include market trends and company updates

These insights serve as crucial points for investors evaluating Avidity Biosciences in the current financial landscape.

For more detailed analysis and regular updates, make sure to visit our source.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe